Biosimilars Pricing In Medicare Part D Needs Legislative Fix, Avalere Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Requiring 50% discount for biosimilars in the coverage gap or establishing biosimilar specialty tier with reduced coinsurance could encourage broader take-up, consulting firm suggests.
You may also be interested in...
Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics
CMS reiterates and elaborates on its position that biosimilars should be subject to brand-level rebates in Medicaid, adding to the perception that the agency’s reimbursement policies do not promote development of biosimilars.
Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics
CMS reiterates and elaborates on its position that biosimilars should be subject to brand-level rebates in Medicaid, adding to the perception that the agency’s reimbursement policies do not promote development of biosimilars.
Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.